Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLIGHT: POTELIGEO and Phototherapy in Early Stage Mycosis Fungoides
NCT06235281Phase 1Suspended
- Sponsor
- Moffitt Cancer Center
- Start
- Jan 2024
- Primary completion
- Sep 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mogamulizumab in mycosis fungoides (MF), sponsored by Moffitt Cancer Center. Primary endpoint: Overall Response Rate at 225 days. Started Jan 2024; status: suspended.
02
Drugs
mogamulizumab
03
Conditions
mycosis fungoides (MF)
Beyond the preview
Go deeper on NCT06235281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06235281.